Benjamin Dallas Flies

Title: The Innovations of Benjamin Dallas Flies

Introduction

Benjamin Dallas Flies is an accomplished inventor based in Rockville, MD. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target specific proteins involved in immune responses. His work has the potential to impact therapeutic strategies for various diseases.

Latest Patents

Benjamin Dallas Flies holds a patent for "Antibodies for Siglec-15 and methods of use thereof." This patent describes Siglec-15 binding molecules, which are typically antibodies or antigen-binding fragments that immunospecifically bind to Siglec-15. The patent also includes Siglec-15 ligand-binding molecules, which can be Siglec-15 polypeptides or fusion proteins. Furthermore, the patent outlines methods for using these molecules to reduce Siglec-15 mediated immunosuppression in subjects in need.

Career Highlights

Flies is currently employed at NextCure, Inc., where he continues to advance his research in immunology and therapeutic applications. His innovative work has positioned him as a key figure in the development of new treatments that harness the immune system.

Collaborations

He collaborates with notable colleagues, including Linda Liu and Solomon Langermann, who contribute to the research and development efforts at NextCure, Inc. Their combined expertise enhances the potential for groundbreaking discoveries in the field.

Conclusion

Benjamin Dallas Flies exemplifies the spirit of innovation in biotechnology through his patent on Siglec-15 binding molecules. His contributions are paving the way for new therapeutic approaches to combat immunosuppression.